Tern Plc Wyld Networks US$1.7 million purchase orders

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things technology businesses, has noted that Wyld Networks AB has announced that it has received purchase orders for its Wyld Connect IoT modules with a total value of US$1.7 million over a four-year period, starting in April 2022. Tern holds 58.7% of Wyld Networks’ issued share capital, which is quoted on the Nasdaq First North Growth Market in Stockholm.

The Wyld Connect solution being supplied will allow the customer, a South African company, to deploy IoT sensors in the agricultural sector to collect data directly from satellites.

Wyld’s sensor-to-satellite module suite with LoRaWAN®* allows IoT sensors to communicate directly from sensor to Low Earth Orbit satellites or in conjunction with terrestrial LoRa networks. Wyld’s modems, devices, and embedded technology are designed to enable communication with the cloud, no matter the location, providing global IoT coverage.

The UN’s Food and Agriculture Organisation has predicted that global food production in 2050 will need to be 70% higher than in 2009, as the world population grows by over a third, almost all in developing countries. To meet this increase in food demand, agriculture is rapidly adopting IoT sensors and devices to collect data from field to make informed decisions that can increase the yield of crops and reduce the waste of water.

Commenting, Alastair Williamson, CEO of Wyld Networks said: “We are pleased to announce the receipt of these purchase orders. Wyld is actively engaged with customers in piloting the service and as part of our programme we are engaged in commercial discussions to solicit purchase orders with multiple customers for the Wyld Connect IoT module ahead of the commercial launch of the service.”

*The LoRaWAN® specification, developed and maintained by the LoRa Alliance®, is a Low Power, Wide Area networking protocol designed to wirelessly connect battery operated ‘things’ to the internet in regional, national or global networks, and targets key IoT requirements such as bi-directional communication, end-to-end security, mobility and localization services.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Search